Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1)

Diabet Med. 2009 Feb;26(2):189-90. doi: 10.1111/j.1464-5491.2008.02645.x.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dipeptidyl-Peptidase IV Inhibitors / pharmacology
  • Dipeptidyl-Peptidase IV Inhibitors / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Gliclazide / therapeutic use
  • Glycated Hemoglobin / metabolism*
  • Hepatocyte Nuclear Factor 1-alpha / drug effects
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Middle Aged
  • Pioglitazone
  • Pyrazines / pharmacology
  • Pyrazines / therapeutic use*
  • Rosiglitazone
  • Sitagliptin Phosphate
  • Thiazolidinediones / therapeutic use
  • Triazoles / pharmacology
  • Triazoles / therapeutic use*

Substances

  • Dipeptidyl-Peptidase IV Inhibitors
  • Glycated Hemoglobin A
  • Hepatocyte Nuclear Factor 1-alpha
  • Hypoglycemic Agents
  • Pyrazines
  • Thiazolidinediones
  • Triazoles
  • Rosiglitazone
  • Gliclazide
  • Sitagliptin Phosphate
  • Pioglitazone